Trials / Recruiting
RecruitingNCT07068932
A Clinical Study of SHR-4506 Injection in Patients With Malignant Tumors
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-4506 Injection in Patients With Malignant Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 102 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the safety and tolerability of SHR-4506 Injection in patients with malignant tumors and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-4506 Injection | SHR-4506 injection. |
Timeline
- Start date
- 2025-07-22
- Primary completion
- 2027-02-01
- Completion
- 2027-08-01
- First posted
- 2025-07-16
- Last updated
- 2025-08-26
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07068932. Inclusion in this directory is not an endorsement.